Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial

BACKGROUND: The efficacy of crizotinib treatment for recurring EML4‐ALK‐positive non‐small cell lung cancer (NSCLC) previously treated with alectinib is unclear. Based on our preclinical findings regarding hepatocyte growth factor/mesenchymal epithelial transition (MET) pathway activation as a poten...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Harada, Daijiro, Isozaki, Hideko, Kozuki, Toshiyuki, Yokoyama, Toshihide, Yoshioka, Hiroshige, Bessho, Akihiro, Hosokawa, Shinobu, Takata, Ichiro, Takigawa, Nagio, Hotta, Katsuyuki, Kiura, Katsuyuki
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2021
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7919114/
https://ncbi.nlm.nih.gov/pubmed/33470536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13825
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados